6/12/2025

WALTHAM, Mass. & GENEVA, June 12, 2025--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults

Source: Yahoo

6/10/2025

WALTHAM, Mass. & GENEVA, Switzerland, June 10, 2025--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and

Source: Yahoo

6/9/2025

Presenter SpeechUnknown Analyst All right. Great. We're just about at time, so let's get started. Our next presentation is with Innoviva. I'm very pleased to welcome Pavel Raifeld, CEO. And my name

Source: Finnhub

6/8/2025

Discover how Innoviva's diversified model drives growth through GSK royalties and specialty therapeutics.

Source: SeekingAlpha

6/3/2025

BURLINGAME, Calif., June 03, 2025--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June:

Source: Yahoo

5/20/2025

WALTHAM, Mass., May 20, 2025--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the United States commercial availability of ZEVTERA® (ceftobiprole medocaril sodium for injection), the newest addition to the Company’s growing antibiotic portfolio. ZEVTERA is the only U.S. Food and Drug Administration (FDA) approved advanced-generation cephalosporin indicated to treat adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (

Source: Yahoo

5/20/2025

Innoviva Inc: * ZEVTERA® , AN ADVANCED-GENERATIONCEPHALOSPORINANTIBIOTIC NOW COMMERCIALLY AVAILABLE IN THE U.S. TO TREAT THREETYPES OF BACTERIAL INFECTIONSSource text:Further...

Source: Finnhub

5/8/2025

We recently published a list of 10 Stocks with Insanely High PE Ratios Insiders Are Selling. In this article, we are going to take a look at where Innoviva, Inc. (NASDAQ:INVA) stands against other stocks with insanely high PE ratios insiders are selling. The U.S. stock market has turned into a theater of extremes right […]

Source: Yahoo

5/8/2025

BURLINGAME - Innoviva, Inc. , a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics , and a...

Source: Finnhub

5/7/2025

BURLINGAME, Calif. AP) — Innoviva Inc. INVA) on Wednesday reported a loss of $46.6 million in its first quarter.

Source: Yahoo

5/7/2025

BURLINGAME, Calif., May 07, 2025--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2025, and highlighted select corporate progress and achievements.

Source: Yahoo

4/11/2025

Source: SeekingAlpha

4/10/2025

With its stock down 4.2% over the past week, it is easy to disregard Innoviva (NASDAQ:INVA). It is possible that the...

Source: Yahoo